The charity said it is having to streamline operations – including job cuts and halting certain programmes of work – as funding is decimated by the coronavirus pandemic
News
US committee backs terlipressin approval for HRS-1
HRS-1 is an acute and life-threatening syndrome with a survival time of just two weeks if left untreated
AZ unveils detailed data from THALES trial
The results show a 17% cut in the risk of subsequent stroke in patients taking Brilinta and aspirin
UK’s MHRA allows early access to lumasiran for ultra-rare disease
Lumasiran targets primary hyperoxaluria type 1 (PH1), which affects just around 90 people in the UK and one to three individuals per million in Europe
Janssen’s Tremfya wins psoriatic arthritis approval
The drug is the first IL-23 inhibitor approved for the condition
Radiotherapy in fewer doses safe for early breast cancer
10-year study shows lower total dose of radiotherapy delivered in fewer but larger doses is safe
FDA committee backs GSK’s multiple myeloma drug
If approved, belantamab mafodotin will be a first-in-class anti-BCMA therapy for relapsed/refractory multiple myeloma
Study indicates lockdown significantly reduced coronavirus
The findings provide a baseline for further research into how the virus is spreading in England
Tecentriq misses mark in ovarian cancer trial
The drug did not extend progression-free survival in patients with newly diagnosed advanced stage ovarian cancer
US fast tracks Pfizer/BioNTech coronavirus vaccines
The mRNA-based vaccines are currently being evaluated in Phase I/II clinical trials in Germany and the US
ICR/Cyclacel scientists discover new cancer drug
Fadraciclib is a dual inhibitor of CDK2 and CDK9
‘Prepare now for winter COVID-19 peak’, says Academy of Medical Sciences
COVID-19 deaths could reach 119,000 between September 2020 and June 2021 if no action is taken
Clinigen’s ALS therapy bags US orphan status
Clinigen has bagged a US orphan drug designation (ODD) for its investigational Amyotrophic Lateral Sclerosis (ALS) treatment aldesleukin.
NICE links with Colombia’s Institute of Health Technology Assessment
The two agencies have agreed to share research and knowledge
Experimental motor neurone disease therapy shows early promise
Phase I/II study results demonstrate proof-of-concept and proof-of-biology of tofersen
